Contributions of LeanMassLars

Contributions by LeanMassLars, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 9,182 edits includes activity predating the current log.

1. 08:50, 12 Jul 2026 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 m give the incidence with its denominator
2. 10:20, 19 May 2026 (diff | hist) Amylin receptor agonist 5,245 ±0 fix the amino-acid substitution — position 8, not position 2
3. 05:49, 10 May 2026 (diff | hist) Triple agonist 4,269 ±0 the storage condition applies to the unopened pen; say so
4. 13:20, 27 Mar 2026 (diff | hist) Talk:Sarcopenia 611 +101 /* Strength first, mass second */ reply
5. 11:19, 2 Mar 2026 (diff | hist) Qingdao Saber Technology Pharmaceutical 14,372 +642 expand §Notability and coverage
6. 13:15, 18 Feb 2026 (diff | hist) Talk:Body composition assessment 611 +136 /* Bioimpedance and hydration */ reply
7. 20:24, 14 Feb 2026 (diff | hist) LEADER trial 4,799 ±0 cite the trial publication rather than the sponsor press release
8. 23:22, 11 Dec 2025 (diff | hist) Peptide aggregation 5,516 ±0 m add the plate-count expression and define its terms
9. 15:17, 29 Nov 2025 (diff | hist) Good manufacturing practice 5,123 ±0 m add the patent-expiry statement, attributed and dated
10. 16:53, 27 Nov 2025 (diff | hist) Weight regain after discontinuation 4,670 ±0 m give the event rate per 100 patient-years as in the source
11. 14:46, 9 Nov 2025 (diff | hist) Exenatide 5,754 ±0 copyedit
12. 11:11, 8 Nov 2025 (diff | hist) Personal importation policy 4,121 ±0 clarify that personal importation and commercial importation are different questions
13. 20:34, 6 Nov 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 14,199 +226 add category for suppliers in China
14. 14:22, 18 Oct 2025 (diff | hist) Syringe dead space 8,611 ±0 correct the label on the second column — that is volume, not mass
15. 05:31, 14 Jul 2025 (diff | hist) Peptide aggregation 5,194 ±0 add the peptide-content point: area percent alone cannot give a mass
16. 20:32, 23 Jun 2025 (diff | hist) Aspiration risk under anaesthesia 4,377 +466 m expand §Interpretation
17. 19:35, 15 Apr 2025 (diff | hist) Janoshik Analytical 4,969 +843 add the difference between a batch certificate and a lot-specific one
18. 07:07, 9 Apr 2025 (diff | hist) Multi-dose vial 11,251 +853 expand §Reconstituted peptides and multiple withdrawal
19. 21:04, 4 Apr 2025 (diff | hist) Peptide content 6,898 +351 m add the figure for the chromatogram and caption its axes
20. 12:40, 26 Feb 2025 (diff | hist) Beta cell function 4,916 +588 m rm a duplicated category
21. 09:53, 17 Feb 2025 (diff | hist) Hypoglycaemia 3,743 +266 state that no head-to-head comparison of tolerability exists for these two
22. 06:48, 17 Feb 2025 (diff | hist) Adverse effects of GLP-1 receptor agonists 4,695 +213 m fix hyphenation per PP:MOS
23. 09:54, 6 Feb 2025 (diff | hist) Peptide aggregation 3,901 +786 add the detection wavelength
24. 20:06, 10 Jan 2025 (diff | hist) VendorInvestigate 3,483 +43 clarify that a signature on a certificate is a release, not a verification
25. 14:58, 28 Nov 2024 (diff | hist) Reconstitution of lyophilised peptides 3,676 +558 sentence case in headings per PP:MOS
26. 23:49, 22 Nov 2024 (diff | hist) Loss on drying 2,569 ±0 convert the method-comparison paragraph to a table
27. 08:35, 14 Oct 2024 (diff | hist) TRIUMPH trial programme 1,956 ±0 m add the trial acronym expansion at first use
28. 03:33, 30 Sep 2024 (diff | hist) FLOW trial 1,198 ±0 expand §Results
29. 04:53, 14 Sep 2024 (diff | hist) Weight regain after discontinuation 1,814 +613 expand §Interpretation
30. 15:16, 27 Aug 2024 (diff | hist) Adverse effects of GLP-1 receptor agonists 2,614 +31 rm the reassurance sentence; the article should report, not reassure